Value investing message boards image Log on |  Join ($$) Stock market forums image VF "How To" Guide        Welcome, guest! Learn about guest access                       
ValueForum.com Home
• Related Discussion Forum Messages
As a ValueForum member, this section would contain XLRN message board posts where the ticker symbol XLRN has been mentioned by ValueForum members in posts. Learn more about guest access, and benefits of membership -- we hope you will consider joining ValueForum or trying out our service with a 24 hour trial pass.

• Latest XLRN SEC Filings

Filings Format Description Filing Date File/Film Number
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001179110-18-013519 Size: 11 KB
2018-12-06
8-K  Documents Current report, items 7.01, 8.01, and 9.01
Acc-no: 0001280600-18-000065 (34 Act)  Size: 10 MB
2018-12-03 001-36065
181212841
10-Q  Documents   Interactive Data Quarterly report [Sections 13 or 15(d)]
Acc-no: 0001280600-18-000063 (34 Act)  Size: 5 MB
2018-10-30 001-36065
181147092
8-K  Documents Current report, items 2.02 and 9.01
Acc-no: 0001280600-18-000062 (34 Act)  Size: 152 KB
2018-10-30 001-36065
181147061
SC 13G/A  Documents [Amend] Statement of acquisition of beneficial ownership by individuals
Acc-no: 0000080255-18-002886 (34 Act)  Size: 6 KB
2018-10-10 005-87630
CT ORDER  Documents Confidential treatment order
Acc-no: 9999999997-18-007615 (33 Act)  Size: 13 KB
2018-09-04 333-190417
181051558
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001179110-18-011049 Size: 8 KB
2018-08-31
10-Q  Documents   Interactive Data Quarterly report [Sections 13 or 15(d)]
Acc-no: 0001280600-18-000057 (34 Act)  Size: 5 MB
2018-08-02 001-36065
18988675
8-K  Documents Current report, items 2.02 and 9.01
Acc-no: 0001280600-18-000055 (34 Act)  Size: 159 KB
2018-08-02 001-36065
18988524
8-K  Documents Current report, items 8.01 and 9.01
Acc-no: 0001280600-18-000050 (34 Act)  Size: 68 KB
2018-07-26 001-36065
18972103
More XLRN SEC Filings


Related news from
Wed, 05 Dec 2018
21:30:00 +0000
Acceleron Announces Luspatercept Phase 3 MEDALIST and BELIEVE Presentations Selected for “Best of ASH” by the American Society of Hematology
Acceleron Pharma Inc. (XLRN) today announced that the presentations of the MEDALIST and BELIEVE Phase 3 trial results of luspatercept in patients with lower-risk myelodysplastic syndromes (MDS) and beta-thalassemia associated anemias, respectively, were selected for “Best of ASH” by the American Society of Hematology at its 60th Annual Meeting & Exposition in San Diego. Luspatercept is an investigational therapy that is part of a global collaboration between Acceleron and Celgene. “Having both the MEDALIST and BELIEVE trials included in the Best of ASH session at the close of the annual meeting is extraordinarily gratifying,” said Habib Dable, President and Chief Executive Officer of Acceleron.
Mon, 03 Dec 2018
23:09:11 +0000
Celgene (CELG) Announces Various Cancer Data at ASH 2018
Celegne (CELG) presents data from several cancer studies at the annual meeting of American Society of Hematology (ASH).
Mon, 03 Dec 2018
12:30:00 +0000
Detailed Research: Economic Perspectives on Honeywell International, Tabula Rasa Healthcare, El Pollo Loco, Acceleron Pharma, vTv Therapeutics, and 22nd Century Group — What Drives Growth in Today's Competitive Landscape
NEW YORK, Dec. 03, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Sat, 01 Dec 2018
22:00:00 +0000
Celgene Corporation and Acceleron Pharma Announce Results of the Phase 3 BELIEVE Trial Evaluating Luspatercept in Adult Patients with Beta-Thalassemia at ASH 2018
Pivotal phase 3 data demonstrated treatment with investigational luspatercept resulted in significant reduction of transfusion burden compared to placebo
Sat, 01 Dec 2018
12:03:00 +0000
Top Biotech Stocks to Watch at ASH 2018
Investors have been waiting patiently for some important updates expected at a key medical conference.
Wed, 28 Nov 2018
12:00:00 +0000
Acceleron Receives FDA Fast Track Designation for ACE-083 in Charcot-Marie-Tooth Disease
Acceleron Pharma Inc. (XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced that the United States Food and Drug Administration (FDA) has granted Fast Track designation to ACE-083, the Company’s locally-acting “Myostatin+” muscle agent, for the treatment of patients with Charcot-Marie-Tooth disease (CMT). “We’re pleased that the FDA has granted this designation for ACE-083,” said Robert K. Zeldin, M.D., Chief Medical Officer of Acceleron.
Tue, 27 Nov 2018
12:00:00 +0000
Acceleron to Host Conference Call and Webcast to Review MEDALIST and BELIEVE Phase 3 Trial Presentations of Luspatercept at the 60th American Society of Hematology Annual Meeting
Acceleron Pharma Inc. (XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced it will host a conference call and live audio webcast on Monday, December 3, 2018 at 9:00 a.m. EST to review the MEDALIST and BELIEVE Phase 3 trial presentations of luspatercept at the 60th American Society of Hematology (ASH) Annual Meeting and Exposition taking place on December 1-4, 2018 in San Diego, California.
Mon, 26 Nov 2018
12:00:00 +0000
Acceleron to Participate in Two Upcoming Healthcare Investor Conferences
Acceleron Pharma Inc. , a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced that senior management will participate in two upcoming healthcare investor conferences.
Tue, 20 Nov 2018
01:46:00 +0000
3 Top Healthcare Stocks to Buy Right Now
You could miss out on market-beating returns if you don't have these top stocks in your portfolio.
Sat, 17 Nov 2018
13:31:00 +0000
My Top 3 Favorite Clinical-Stage Biotech Stocks to Buy
These biotech upstarts have deep pockets and late-stage pipelines that could make them savvy buys.
Wed, 07 Nov 2018
14:16:00 +0000
3 Cancer Stocks to Watch in December
Shares of these biotechs could surge following presentations at an important medical conference.
Wed, 07 Nov 2018
12:00:00 +0000
Acceleron Announces Preclinical Presentations on Sotatercept in Pulmonary Arterial Hypertension at the 2018 American Heart Association Scientific Session
Acceleron Pharma Inc. , a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced plans to deliver three preclinical presentations on sotatercept in Pulmonary Arterial Hypertension at the 2018 American Heart Association Scientific Session in Chicago, IL, November 10-12, 2018.
Sat, 03 Nov 2018
18:16:11 +0000
Edited Transcript of XLRN earnings conference call or presentation 30-Oct-18 8:30pm GMT
Q3 2018 Acceleron Pharma Inc Earnings Call
Thu, 01 Nov 2018
13:01:00 +0000
Acceleron Announces that Phase 3 Results from the MEDALIST and BELIEVE Trials of Luspatercept will be Presented at the 60th American Society of Hematology Annual Meeting
Acceleron Pharma Inc. (XLRN) today announced that results from the MEDALIST and BELIEVE Phase 3 trials of luspatercept in patients with low-to-intermediate risk myelodysplastic syndromes (MDS) and transfusion-dependent beta-thalassemia, respectively, will be presented at the 60th American Society of Hematology (ASH) Annual Meeting & Exposition in San Diego, California, on December 1-4, 2018. Luspatercept is being developed as part of a global collaboration between Acceleron and Celgene.
Tue, 30 Oct 2018
21:25:09 +0000
Acceleron Pharma (XLRN) Reports Q3 Loss, Misses Revenue Estimates
Acceleron (XLRN) delivered earnings and revenue surprises of 3.08% and -5.62%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Tue, 30 Oct 2018
20:20:10 +0000
Acceleron: 3Q Earnings Snapshot
The Cambridge, Massachusetts-based company said it had a loss of 63 cents per share. The results exceeded Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research ...
Tue, 30 Oct 2018
20:05:00 +0000
Acceleron Reports Third Quarter 2018 Operating and Financial Results
– MEDALIST and BELIEVE Phase 3 trial results in myelodysplastic syndromes and beta-thalassemia, respectively, are expected to be presented at the 60th American Society of Hem
Wed, 24 Oct 2018
11:20:00 +0000
Research Report Identifies Cato, Roadrunner Transportation, Talend S.A, Vi, MannKind, and Acceleron Pharma with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
NEW YORK, Oct. 24, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Tue, 23 Oct 2018
11:00:00 +0000
Acceleron to Webcast Third Quarter 2018 Operating and Financial Results on October 30, 2018
Acceleron Pharma Inc. (XLRN) today announced it will host a webcast and conference call on Tuesday, October 30, 2018 at 4:30 p.m. EDT to discuss its third quarter 2018 operating and financial results. The webcast will be accessible under "Events & Presentations" in the Investors/Media page of the company's website at www.acceleronpharma.com. The archived webcast will be available for replay on the Acceleron website approximately two hours after the event.
Tue, 16 Oct 2018
11:00:00 +0000
Acceleron to Host Pulmonary Arterial Hypertension Research and Development Deep Dive Event on November 16, 2018 in New York City
Acceleron Pharma Inc. (XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced it will webcast a live presentation from its Pulmonary Arterial Hypertension (PAH) Research and Development Deep Dive event on Friday, November 16, 2018. The meeting will feature presentations from leading PAH clinicians and researchers along with Acceleron senior management, who will discuss the current PAH treatment landscape and the importance of BMP signaling—a molecular pathway fundamental to all forms of the disease. The Company will highlight its latest preclinical research on sotatercept, its lead product candidate in PAH, which will have been presented at the American Heart Association Scientific Sessions on November 10-12, 2018.



"ValueForum is an active, private, online discussion community for stock & bond market investing. In discussion forums divided into finely grained topics, you will find sophisticated investors trading tips, research, and due diligence on value stocks, income investments, forex, market news, and more. Join in - trade ideas, strategies, current news, via our unique message bulletin boards, stock ratings system, and other online tools specifically geared toward our community."

Random member testimonial: "ValueForum is a great group of very smart, sophisticated investors. We have several professionals on board managing millions of dollars, and "average Joe" investors that beat the pants off of Wall Street professionals year in and year out. ValueForum will expose you to a wealth of ideas and sectors, and keep you ahead of the curve." more testimonials »

Email / About | Privacy | Terms of Use | How To / FAQ | Msg Ticker | VF Home | My.vf | BDCs.vf | Energy.vf | REITs.vf | TA.vf
 
Nothing in ValueForum.com is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by ValueForum.com. ©2003 - 2018, Powered in part by Ticker TechnologiesContact Us

Stock Market Investing Forum - Trading Tips & Research - Online Message Boards